As a matter relating to controlling shareholders, Suzuken Co., Ltd. holds 20.1% of the company\u2019s shares and the strategic business alliance is ongoing. Transactions via consolidated subsidiaries involve pharmaceutical purchases, with terms comparable to those with other business partners. The company maintains its independence in management decisions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2796","jir_company_name":"PharmaRaise Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2796-20260824-01.pdf","jir_short_summary":"As a matter relating to controlling shareholders, Suzuken Co., Ltd. holds 20.1% of the company\u2019s shares and the strategic business alliance is ongoing. Transactions via consolidated subsidiaries involve pharmaceutical purchases, with terms comparable to those with other business partners. The company maintains its independence in management decisions.","jir_summary":"### Overview of Matters Related to Controlling Shareholders, etc.\nThis report discloses matters concerning the parent company, controlling shareholders, and other related parties, and clearly states that Suzuken Co., Ltd. owns 20.1% of our company's shares. The two companies have maintained a close cooperative relationship through the business capital alliance agreement signed on November 10, Reiwa 5. In addition, our group's consolidated subsidiaries procure pharmaceuticals, etc., from Suzuken's group, and there are currently no personnel connections. Management decisions and business execution are led by our company, ensuring independence.\n\n### Transactions and Amounts\nTransactions with related parties by our company are considered none. For transactions between consolidated subsidiaries and related parties, during the period from June 1, Reiwa 7 to May 31, Reiwa 8, procurement of pharmaceuticals and other items was the main transaction, with transaction amounts reaching 11,635 million yen (accounts payable). Terms of these transactions are determined under the same conditions as transactions with unrelated counterparties with whom our subsidiaries have no relationship.","jir_financial_highlights":"Voting rights ownership ratio: 20.1 (Unknown)\nTransactions with related parties: 11,635 (Unknown)","jir_category":"","jir_hashtags":"#PharmaRaiseHoldings, #ControllingShareholderMatter, #RelatedTransactions","jir_key_figures":"Voting rights ownership: 20.1%\nTransaction amount: 11,635 million yen\nShareholder: Suzuken Co., Ltd.\nTransaction period: June 1, Reiwa 7 \u2013 May 31, Reiwa 8","jir_meta_title":"PharmaRaise Holdings \u2013 Matters Related to Controlling Shareholders, etc. | August 2026","jir_meta_description":"Disclosure of matters related to controlling shareholders for PharmaRaise Holdings. Highlights include Suzuken's 20.1% shareholding and ongoing collaboration, and the status of transactions by consolidated subsidiaries.","jir_og_title":"Disclosure of PharmaRaise Holdings' Controlling Shareholder Matters","jir_og_description":"Summary of Suzuken's 20.1% shareholding and ongoing business-capital alliance, and consolidated subsidiary transaction status.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59671,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-106286","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n